MIR22HG

Summary

MIR22HG (MIR22 host gene, HGNC:28219) is a long non-coding RNA gene on chromosome 17p13.3.

Predicted to act upstream of or within response to wounding. Predicted to be part of RISC complex.

Source: NCBI Gene 84981 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28219
Approved symbol	MIR22HG
Name	MIR22 host gene
Location	17p13.3
Locus type	RNA, long non-coding
Status	Approved
Aliases	MGC14376, DKFZp686O06159
Ensembl gene	ENSG00000186594
Ensembl biotype	lncRNA
Entrez	84981
RNAcentral	URS0002A1467C — lncRNA, 2592 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 87 — 87 lncRNA

ENST00000334146, ENST00000570416, ENST00000571091, ENST00000571595, ENST00000573075, ENST00000573127, ENST00000574016, ENST00000574306, ENST00000575626, ENST00000576489, ENST00000576749, ENST00000577164, ENST00000608198, ENST00000608245, ENST00000608913, ENST00000609398, ENST00000609442, ENST00000609990, ENST00000610106, ENST00000685207, ENST00000686184, ENST00000686705, ENST00000688431, ENST00000689051, ENST00000689672, ENST00000690262, ENST00000691301, ENST00000691432, ENST00000691506, ENST00000691689, ENST00000701645, ENST00000702134, ENST00000742856, ENST00000742857, ENST00000742858, ENST00000742859, ENST00000742860, ENST00000742861, ENST00000742862, ENST00000742863, ENST00000742864, ENST00000742865, ENST00000742866, ENST00000742867, ENST00000742868, ENST00000742869, ENST00000742870, ENST00000742871, ENST00000742872, ENST00000742873, ENST00000742874, ENST00000742875, ENST00000742876, ENST00000742877, ENST00000742878, ENST00000742879, ENST00000742880, ENST00000742881, ENST00000742882, ENST00000742883, ENST00000742884, ENST00000742885, ENST00000742886, ENST00000742887, ENST00000742888, ENST00000742889, ENST00000742890, ENST00000742891, ENST00000742892, ENST00000742893, ENST00000742894, ENST00000742895, ENST00000742896, ENST00000742897, ENST00000742898, ENST00000742899, ENST00000742900, ENST00000742901, ENST00000742902, ENST00000742903, ENST00000742904, ENST00000742905, ENST00000742906, ENST00000742907, ENST00000742908, ENST00000742909, ENST00000742910

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000334146 — 4 exons

Exon	Start	End
ENSE00001333746	1711447	1712399
ENSE00001490857	1714371	1714453
ENSE00002026073	1713703	1714014
ENSE00004080823	1716130	1716289

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 97.72.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.4865 / max 356.4568, expressed in 1788 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
163777	14.0035	1747
163779	2.1583	1208
163780	1.8324	1017
163778	0.4923	248

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of stomach	UBERON:0001199	97.72	gold quality
left uterine tube	UBERON:0001303	97.43	gold quality
right adrenal gland cortex	UBERON:0035827	95.56	gold quality
left adrenal gland cortex	UBERON:0035825	95.30	gold quality
gall bladder	UBERON:0002110	95.23	gold quality
left adrenal gland	UBERON:0001234	95.20	gold quality
right adrenal gland	UBERON:0001233	94.92	gold quality
right coronary artery	UBERON:0001625	94.76	gold quality
placenta	UBERON:0001987	94.72	gold quality
left coronary artery	UBERON:0001626	94.71	gold quality
adrenal gland	UBERON:0002369	94.70	gold quality
apex of heart	UBERON:0002098	94.41	gold quality
adrenal tissue	UBERON:0018303	94.40	gold quality
duodenum	UBERON:0002114	94.17	gold quality
hindlimb stylopod muscle	UBERON:0004252	93.73	gold quality
stromal cell of endometrium	CL:0002255	93.65	gold quality
thoracic aorta	UBERON:0001515	93.64	gold quality
monocyte	CL:0000576	93.59	gold quality
smooth muscle tissue	UBERON:0001135	93.56	gold quality
ascending aorta	UBERON:0001496	93.52	gold quality
heart left ventricle	UBERON:0002084	93.43	gold quality
tibial artery	UBERON:0007610	93.32	gold quality
popliteal artery	UBERON:0002250	93.29	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.21	gold quality
bone marrow	UBERON:0002371	93.05	gold quality
heart	UBERON:0000948	92.87	gold quality
right atrium auricular region	UBERON:0006631	92.66	gold quality
upper lobe of left lung	UBERON:0008952	92.49	gold quality
lower esophagus muscularis layer	UBERON:0035833	92.37	gold quality
leukocyte	CL:0000738	92.31	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.54

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 25)

• six novel lncRNAs (CDKN2B-AS1, MIR22HG, GABPB1-AS1, FLJ33630, LINC00152, and LINC0541471_v2) that respond to model chemical stresses (cycloheximide, hydrogen peroxide, cadmium, or arsenic) in hiPSCs. (PMID:25171338)
• Results found that elevated expression of C17orf91 was observed in omental metastases when compared with matched primary ovarian tumors and loss-of-function studies further demonstrated that C17orf91 repression impaired migration, invasion and viability of ovarian cancer cells. (PMID:27535740)
• Analysis of 918 lung cancer and normal lung tissues and lung cancer cell lines revealed that MIR22HG was significantly downregulated in lung cancer; this decreased expression was associated with poor patient survival. MIR22HG bound and stabilized the YBX1 protein. Silencing of MIR22HG triggered both cell survival and cell death signaling through dysregulation of the oncogenes YBX1, MET, and p21. (PMID:29669758)
• LncRNA MIR22HG could act as a tumor suppressor and inhibited EC cells proliferation through regulating miR-141-3p/DAPK1 axis. (PMID:29775889)
• MiR-22 was up-regulated in CD4+ T cells in peripheral blood and intestinal mucosa tissues of inflammatory intestinal disease patients, which could promote Th17 cell differentiation via targeting HDAC4 to be involved in inflammatory intestinal disease progression (PMID:29880327)
• results suggested MIR22HG could serve as a novel biomarker for thyroid cancer (PMID:30539522)
• MIR22HG inhibited HCC progression in part through the miR-10a-5p/NCOR2 signaling. (PMID:30680848)
• the results of the present study show that MIR22HG repressed cell proliferation, migration and invasion in CCA by negatively regulating the Wnt/beta-catenin signaling pathway. MIR22HG may be a novel target for diagnosis and therapy in CCA. (PMID:30856284)
• Abrogation of MIR22HG inhibited cell proliferation, colony formation, invasion and migration in EAC (esophageal adenocarcinoma) cell lines. Mechanistically, MIR22HG silencing decreased the expression of STAT3/c-Myc/p-FAK proteins and induced apoptosis in EAC cell lines. (PMID:31291201)
• E2F6-Mediated Downregulation of MIR22HG Facilitates the Progression of Laryngocarcinoma by Targeting the miR-5000-3p/FBXW7 Axis. (PMID:32094308)
• MIR22HG acts as a tumor suppressor via TGFbeta/SMAD signaling and facilitates immunotherapy in colorectal cancer. (PMID:32127004)
• Long noncoding RNA MIR22HG is down-regulated in prostate cancer. (PMID:32233607)
• MIR22HG regulates miR-486/PTEN axis in bladder cancer to promote cell proliferation. (PMID:32500915)
• Long non-coding RNA MIR22HG promotes osteogenic differentiation of bone marrow mesenchymal stem cells via PTEN/ AKT pathway. (PMID:32732881)
• Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers. (PMID:33267888)
• LncRNA MIR22HG is downregulated in adenomyosis and upregulates miR-2861 through demethylation to inhibit endometrial cell proliferation. (PMID:33624428)
• Identification of circulating miR-22-3p and let-7a-5p as novel diagnostic biomarkers for rheumatoid arthritis. (PMID:33635234)
• LncRNA MIR22HG promotes osteoarthritis progression via regulating miR-9-3p/ADAMTS5 pathway. (PMID:34187303)
• Overexpression of Long Non-Coding RNA MIR22HG Represses Proliferation and Enhances Apoptosis via miR-629-5p/TET3 Axis in Osteosarcoma Cells. (PMID:34373436)
• MIR22HG inhibits breast cancer progression by stabilizing LATS2 tumor suppressor. (PMID:34446703)
• [Pan-cancer analysis of the expression pattern of long non-coding RNA MIR22HG]. (PMID:35527483)
• Long non-coding RNA MIR22HG suppresses cell proliferation and promotes apoptosis in prostate cancer cells by sponging microRNA-9-3p. (PMID:35611601)
• Long non-coding RNA MIR22HG inhibits the proliferation and migration, and promotes apoptosis by targeting microRNA-9-3p/ SOCS1 axis in small cell lung cancer cells. (PMID:37479878)
• Long non-coding RNA MIR22HG suppresses the chondrogenic differentiation of human adipose-derived stem cells by interacting with CTCF to upregulate CRLF1. (PMID:37910254)
• LncRNA MIR22HG/microRNA-9-3p/IGF1 in nonalcoholic steatohepatitis, the ceRNA network increases fibrosis by inhibiting autophagy and promoting pyroptosis. (PMID:38011754)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.